The molecular pathology of somatotrophinomas has been investigated by a combined search for dominant mutations of the gene encoding the Gsa protein and for recessive mutations involving chromosome 11q13, which contains the gene causing multiple endocrine neoplasia type I (MENI ). Somatotrophinomas and peripheral leukocytes were obtained from thirteen patients with acromegaly; one patient also suffered from MENi. Five DNA probes identifying restriction fragment length polymorphisms from 1 Iq revealed allele loss in pituitary tumors from five (four non-MENI and one MEN1) patients. Deletion mapping revealed that the region of allele loss common to the somatotrophinomas involved 1 1q13. An analysis for similar allelic deletions at 12 other loci from chromosomes 1-5, 7-9, 12-14, and 17 did not reveal generalized allele loss in the somatotrophinomas. These results, which represent the first report of chromosome 11 allele loss occurring in non-MEN1 somatotrophinomas, indicate that a recessive oncogene on 11q13 is specifically involved in the monoclonal development of somatotrophinomas. In addition Gsa mutations were detected in two non-MENi somatotrophinomas, one of which also revealed allele loss of chromosome 11. Thus, our results reveal that the development of somatotrophinomas is associated with alterations in both dominant and recessive oncogenes and further characterization of these genetic abnormalities will help to elucidate the multistep etiology and progression of somatotrophinomas. (J. Clin. Invest. 1993. 2815-2821
Introduction
The development of tumors may be associated with an activation of dominant oncogenes or an inactivation of recessive oncogenes ( 1, 2) , which are also referred to as anti-oncogenes or tumor suppressor genes (3) . A dominantly acting oncogene, due to a point mutation in one copy ofthe gene encoding the a chain of the guanine nucleotide (GTP) binding subunit of the stimulatory regulator of adenylyl cyclase, referred to as the Gs protein, has been demonstrated to be associated with a subset of somatotrophinomas, which are growth hormone (GH)-secreting pituitary tumors (4, 5) . This Gs protein a chain mutation, which is also referred to as a gsp mutation, was found in 40% of somatotrophinomas (5) . In the remaining 60% of somatotrophinomas abnormalities in other genes are likely to be involved. Somatotrophinomas are known to occur in families either as an isolated autosomal dominant endocrinopathy (6, 7) , or as part of the autosomal dominant Multiple Endocrine Neoplasia Type 1 (MEN 1 )' syndrome (8) , which is characterized by the combined occurrence of tumors of the parathyroids, the pancreatic islets, and pituitary. The occurrence of such inherited somatotrophinomas suggests that recessively acting tumor suppressor genes, which are particularly involved in hereditary neoplasms such as retinoblastoma (3) , may be associated with the etiology of some tumors. In order to localize and establish the role of such tumor suppressor genes in the development of a tumor (9, 10) , a demonstration of a loss of tumor heterozygosity, revealed by a comparison of leukocyte and tumor alleles, is required. The tumor suppressor gene causing MEN 1 has been localized to the pericentromeric region of the long arm of chromosome 11 ( 1 q13) (11, 12) , but a previous study of 10 somatotrophinomas (9 non-MEN1 and 1 MEN 1) did not detect allelic deletions involving chromosome 11 ( 13) . This finding contrasts with the observed chromosome 11 allele loss in sporadic non-MEN1 and MENI parathyroid tumors (12) (13) (14) , and it has been proposed that sporadic pituitary tumors may not arise through inactivation of the MEN1 gene ( 15) . In order to investigate this further, we have performed detailed deletion mapping studies using 14 DNA probes from chromosome 11. Our results indicate that a recessive tumor suppressor oncogene in the 1 q 13 region is involved in the monoclonal development ofsporadic non-MEN 1 and MEN1 somatotrophinomas. Thus, somatotrophinomas may arise through activation of dominant oncogenes (4, 5) 18, 19, 20q , and 21q, respectively. The somatotrophinomas from 8 patients (patients 3 to 9 and 11) were assessed for allelic deletions at each ofthese 20 autosomal loci. However, in patients 1,2, 10, 12, and 13 this analysis was limited to 11, 13, 17,9, and 0 loci as sufficient tumor DNA was not available to investigate all of these 20 autosomal loci.
Allele-specific oligonucleotide hybridization. The genomic segments encompassing the two sites of known activating missense mutations of Gsa (Arg201 in exon 8 and Gln227 in exon 9) were amplified by the PCR (26), using an automated DNA thermal cycler (combi thermal reactor TR2, Hybaid, Teddington, Middlesex, UK). In order to improve the yield and specificity for these DNA segments, 2 rounds of PCR amplification in which two pairs of Gsa-specific oligonucleotide primers, designated IL and 1R and 2L and 2R, were used. The DNA sequences of these PCR primers were as follows: IL consisted of 5'GCGCTGTGAACACCCCACGTGTCT 3', and lRof5'CGCAGG-GGGTGGGCGGTCACTCCA; 2L consisted of 5' GTGATCAAG-CAGGCTGACTATGTG 3' and 2R of 5' GCTGCTGGCCACCAC-GAAGATGAT 3'. The complementary sequences from the primers 1 L and 2L were in intron 6 and exon 7, respectively (27) , and those for I R and 2R were in exon 10, with I L being 5'to 2L and I R being 3'to 2R. Thus, the binding sites for 2L and 2R are nested within the segment amplified by 1 L and I R, thereby enhancing the sensitivity and specificity of the PCR amplification as follows: 250 ng of genomic DNA were added to a 25 ,d volume containing 30 pmol each ofprimers 1 L and I R and 1.5 units ofthe heat stable DNA polymerase of Thermus aquaticus (Taq polymerases; BRL, Gaithersburg, MD) (5). The buffers and conditions utilized for PCR were as previously described (5). On completion, 2 Ml ofthe reaction mix and 30 pmol each ofthe nested primers 2L and 2R were utilized for the second round of PCR amplification using conditions previously described (5). 2 Al of the nested PCR product were denatured in 0.4 M sodium hydroxide and 25 mM EDTA for 5 min at room temperature, dot blotted onto nylon filters (Hybond N+; Amersham Corp, Arlington Heights, IL), and crosslinked to the filter by ultraviolet light. The filters were hybridized with y32P end-labeled Pituitary histology
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oligonucleotide probes, which were 20 bases in length and contained either the wild type (WT) sequence of arginine at position 201 (R20 1, codon sequence CGT) or a substitution ofcysteine for arginine at position 201 (R20lC, codon sequence TGT), or a substitution ofhistidine for arginine at position 201 (R201H, codon sequence CAT), or the wild type sequence of glutamine at position 227 (Q227, codon sequence CAG), or a substitution of arginine for glutamine at position 227 (Q227R, each on codon sequence CGG), or a substitution of leucine for glutamine at position 227 (Q227L, codon sequence CTG). The DNA sequences of these oligonucleotide probes, together with hybridization and washing conditions, were as previously described (5, 28) . The results of this allele-specific oligonucleotide analysis were confirmed by direct double-stranded DNA sequencing ofthe leukocyte and tumor DNA, using methods previously described (29 Figure 1 . Analysis of alleles on chromosome 11 in DNA from leukocytes and somatotrophinomas from 13 patients ( Table I ). The leukocyte and somatotrophinoma alleles were determined as shown in Fig. 2 12 (Fig. 2) revealed that the ratio between the retained allele in the tumor DNA to the corresponding leukocyte DNA was 2.36. These data suggest that allele loss in these two somatotrophinomas is followed by reduplication of the remaining portion of one copy of the chromosome. However, an analysis of the remaining three somatotrophinomas from patients 1, 2, and 13, in whom allele loss had been demonstrated (Fig. 1) , did not confirm tumor homozygosity and the data from patient 1 were in keeping with tumor hemizygosity with a tumor/leukocyte allele ratio of less than 0.9. These limited data from a small number of somatotrophinomas indicate that 40% of somatotrophinomas lose part of one copy of chromosome 1 1, and that in some tumors there may be a reduplication of the remaining regional copy of chromosome 1.
The specificity of these allelic deletions for chromosome 11I in the somatotrophinomas was assessed by examining for similar allele loss on 20 other autosomes, utilizing one DNA probe from each chromosome. 12 of the 20 DNA probes proved informative to varying degrees and allele loss was therefore limited to these loci, which were from chromosome I1p35-p33, 2p, 1.00 Figure 3 . Densitometric scans are shown below the corresponding autoradiographs obtained using the probes DI 1S97 and DXS255 from the leukocyte (L) and tumor (T) DNA of patient 5 (Fig. 2) . The intensity (I) and the relative intensity (Ir) which corrects for differences in the amount of DNA of each band are indicated. The results of densitometric scanning confirm the findings of visual assessment, which indicated a loss of tumor heterozygosity. In addition, the relative intensity of the retained tumor allele is twice (0.71 +0.36) that of the corresponding leukocyte allele. Thus, the results of scanning densitometry suggest that in the tumor a reduplication of the retained chromosomal region has occurred, and led to tumor homozygosity in the somatotrophinoma of this patient.
3, 4p16.3, 5q35-qter, 7p22, 8, 9q34, 12q 24.3-qter, 13q12-21, 14q32, and 1l7q. Allele loss which did not involve chromosome 11I was detected in only one somatotrophinoma. This allelic deletion was demonstrated in the tumor of patient 5 (Fig. 2) by the use ofthe probe DlI S7, which has been localized to chromosome I1p35-p33. Thus, the somatotrophinoma of patient 5 was associated with allelic deletions of chromosomes 11I and 1, while the somatotrophinomas of patients 1, 2, and 12 were associated with allele loss that specifically involved chromosome 11. These results indicate that the observed allelic deletions of chromosome 11I in these somatotrophinomas are specific and not part of a generalized loss in these tumors.
Gsp mutations in somatotrophinomas. DNA from eleven of the thirteen somatotrophinomas from patients 1 to 11I (Fig. 1) was available for the investigation of the four tumor gsp mutations that are associated with somatotrophinomas (4, 5, 28). The mutations involving arginine at position 201, which have been designated R20 IlC and R20 1 H, occur in exon 8, and those involving glutamine at position 227, which have been designated Q227R and Q227L, occur in exon 9. A genomic fragment of DNA of 526 base pairs (bp) containing the 3'portion of exon 7, the whole of exons 8 and 9, and the 5' portion of Figure 4 . Analysis of gsp mutations in the somatotrophinomas from patients 1 to 11 (Fig. 1) . The results obtained by utilizing the allele-specific oligonucleotide probes R201 (WT), R20 IC, and R201H and the patients' leukocyte (L) and tumor ( T) DNA are shown, and an analysis revealed abnormalities in the tumor DNA from patients 2 and 8. These findings were confirmed by direct DNA sequence analysis.
DNA. The amplified DNA segments were bound to nylon filters and hybridized at high stringency (5) to radiolabeled oligonucleotide probes that either matched the WT sequence or contained specific single base substitutions. This method for identifying mutations is referred to as allele-specific oligonucleotide (ASO) hybridization, and the results of the analysis with WT R201 and mutant R20 IC and R201 H oligonucleotide probes are shown in Fig. 4 . Hybridization signals were obtained from the leukocyte and tumor DNA of all the patients when using the wild type oligonucleotide probe R201 (WT). However, hybridization signals were obtained only from the tumor DNA of patients 2 and 8 when the mutant R20 IC probe was used, and no hybridization signals were obtained from either the leukocyte or tumor DNA when the mutant R201H was used. Thus, the somatotrophinoma DNA from patients 2 and 8
was associated with a C T mutation in codon 201 (CGT), which resulted in a substitution of cysteine for arginine, whereas the leukocyte DNA from these patients, together with the leukocyte and tumor DNA from the remaining patients, was found not to contain mutant sequences but wild type (i.e., normal) Gsa sequences. These point mutations of codon 201 in exon 8 of the Gsa gene were confirmed by determining the DNA sequence of the amplified DNA segments obtained from the tumor and leukocytes of patients 2 and 8 (data not shown). An analysis with WT Q227 and mutant Q227R and Q227L oligonucleotide probes revealed no abnormalities in the tumor DNA from the 11 patients. Thus, gsp mutations in which cysteine had been substituted for arginine at position 201 were found to be associated with 2 of the 11 somatotrophinomas. One ofthese tumors (patient 2) was also found to be associated with allelic deletions of chromosome 11 ( Fig. 1 ).
Discussion
The results of our study demonstrate that abnormalities of chromosome 11 and gsp mutations are associated with somatotrophinomas. The loss of alleles in these tumors, which were from patients with isolated acromegaly and from a patient in whom acromegaly was part of the MEN1 syndrome, indicates that the development of somatotrophinomas is monoclonal. ( 13) . The failure to detect a loss of heterozygosity in these studies may partly be attributable to the uninformativeness-i.e., the homozygosity-of the peripheral leukocytes for many of the probes used. However, leukocyte heterozygosity was revealed in our 8 patients (patients 3, 4 and 6-1 1) at one or more ofthe loci in 1 1q 13 (Fig. 1 ) . The absence of allele loss in these somatotrophinomas may reflect a limitation of the current techniques to detect small focal abnormalities. Alternatively, this lack of allele loss may indicate a heterogenous origin for the tumors or the different stages-i.e., multiple steps-that occur in tumor development and progression.
Allele loss involving chromosome 1 was observed in one soma-ltotrophinoma ( Fig. 2) and similar abnormalities involving chromosomes 1 and 4 have been reported in two other somatotrophinomas ( 13). These findings suggest that different tumor suppressor genes located on chromosomes 1 1, 1, and 4 may be involved in the multistep progression of somatotrophinomas analogous to that reported for colorectal carcinomas (39) (40) (41) . In addition, the commoner occurrence of allele loss on chromosome 1 1 in these tumors suggests that an allelic deletion on chromosome 11 may be an early event in the development of somatotrophinomas.
Our results, which indicate the involvement of a recessive tumor suppressor gene on chromosome 11 in the development of somatotrophinomas, reveal an additional etiology to that previously reported for a subset of somatotrophinomas (4, 5) . In these tumors, mutations ofthe gene encoding the a chain of the Gs protein, which has been localized to chromosome 20 (42) , behaved like dominantly acting oncogenes. Our investigation for Gsa mutations in 11 of 13 patients with somatotrophinomas revealed gsp mutations in two tumors (Fig. 4) . One of these tumors was also associated with allelic deletions on chromosome 11 (Fig. 1) . Our combined results may help to elucidate further the roles ofthese two mutations, and a genetic model for the development of somatotrophinomas may involve the following possibilities: (a) tumorigenesis may be associated with either an allelic deletion on chromosome 11 or a mutation of G^a; (b) an early mutation of Gsa may initiate a clonal proliferation during which a mitotic disjunction involving an allele loss of chromosome 11 occurs; (c) an allelic deletion ofchromosome 11 precedes a Gsa mutation, which would then convert a small adenoma to a larger proliferative one by enhancing clonal expansion ofthe cell with the allelic deletion; (d) the order in which these mutations occur may not be invariant, and the accumulation of these genetic abnormalities may be more important in the development and progression of the tumor. The results of our study, which have identified the occurrence in somatotrophinomas of either allelic deletions of chromosome 11 or ofgsp mutations, provide support for these genetic models. Further detailed analysis ofour proposed models for the development ofsomatotrophinomas, which are similar to those reported for colorectal tumors (40, 41 ), will help to elucidate the roles of the dominant and recessive oncogenes associated with these growth hormone-secreting pituitary tumors.
